Neurology
-
Randomized Controlled Trial Multicenter Study
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention.
To evaluate whether the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant might be effective for migraine prevention. ⋯ This study provides Class II evidence that in patients with migraine, telcagepant taken daily reduces headache days by 1.4 days per month compared to placebo and causes 2.5% of patients to have elevations of serum ALT levels.